![1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment](/docs/US/2022-10-04/US11458134B2/abs.jpg.600x600.jpg)
- Patent Title: 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
-
Application No.: US16502677Application Date: 2019-07-03
-
Publication No.: US11458134B2Publication Date: 2022-10-04
- Inventor: André Faldt , Heidi Lopez de Diego , Rene Holm , Michael J. Mealy
- Applicant: H. Lundbeck A/S
- Applicant Address: DK Valby
- Assignee: H. Lundbeck A/S
- Current Assignee: H. Lundbeck A/S
- Current Assignee Address: DK Valby
- Agency: Fish & Richardson P.C.
- Priority: DKPA200600824 20060616,DKPA200601223 20060922,DKPA200601384 20061025,DKPA200700427 20070320
- Main IPC: A61K31/495
- IPC: A61K31/495 ; C07D295/096 ; A61K9/14 ; A61P25/22
![1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment](/abs-image/US/2022/10/04/US11458134B2/abs.jpg.150x150.jpg)
Abstract:
1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
Public/Granted literature
Information query
